ENLV Enlivex Therapeutics Ltd
Price (delayed)
$1.01
Market cap
$23.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.73
Enterprise value
$391,499
enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib
Highlights
Enlivex Therapeutics's EPS has soared by 53% YoY and by 26% from the previous quarter
Enlivex Therapeutics's net income has increased by 48% YoY and by 21% from the previous quarter
The company's quick ratio rose by 37% YoY but it fell by 30% QoQ
ENLV's equity is down by 22% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of ENLV
Market
Valuations
Earnings
Shares outstanding
23.65M
Market cap
$23.89M
Enterprise value
$391,499
Price to earnings (P/E)
N/A
Price to book (P/B)
0.94
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$15.89M
Net income
-$15.01M
EBIT
-$15.89M
EBITDA
-$15.34M
Free cash flow
-$12.93M
Per share
Balance sheet
Liquidity
EPS
-$0.73
EPS diluted
-$0.73
Free cash flow per share
-$0.63
Book value per share
$1.07
Revenue per share
$0
TBVPS
$1.35
Total assets
$27.69M
Total liabilities
$4.1M
Debt
$0
Equity
$23.59M
Working capital
$22.19M
Debt to equity
0
Current ratio
6.84
Quick ratio
6.18
Net debt/EBITDA
1.53
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-49.9%
Return on equity
-56.9%
Return on invested capital
-634.6%
Return on capital employed
-66.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENLV stock price
How has the Enlivex Therapeutics stock price performed over time
Intraday
6.32%
1 week
-3.81%
1 month
-15.83%
1 year
-75%
YTD
-13.68%
QTD
4.1%
Financial performance
How have Enlivex Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.89M
Net income
-$15.01M
Gross margin
N/A
Net margin
N/A
Enlivex Therapeutics's net income has increased by 48% YoY and by 21% from the previous quarter
The company's operating income rose by 46% YoY and by 23% QoQ
Growth
What is Enlivex Therapeutics's growth rate over time
Valuation
What is Enlivex Therapeutics stock price valuation
P/E
N/A
P/B
0.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Enlivex Therapeutics's EPS has soared by 53% YoY and by 26% from the previous quarter
ENLV's P/B is 41% below its 5-year quarterly average of 1.5 and 41% below its last 4 quarters average of 1.5
ENLV's equity is down by 22% year-on-year and by 11% since the previous quarter
Efficiency
How efficient is Enlivex Therapeutics business performance
Enlivex Therapeutics's ROE has increased by 20% YoY and by 16% from the previous quarter
Enlivex Therapeutics's ROA has increased by 16% YoY and by 15% from the previous quarter
Dividends
What is ENLV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENLV.
Financial health
How did Enlivex Therapeutics financials performed over time
The total liabilities has contracted by 39% YoY but it has grown by 28% from the previous quarter
The company's quick ratio rose by 37% YoY but it fell by 30% QoQ
ENLV's debt is 100% lower than its equity
ENLV's equity is down by 22% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.